Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Lee Y-, Uchida H, Smith H, Ito A, Sanchez T. The isolation and molecular characterization of cerebral microvessels. Nat Protoc. 2019;14(11):3059-3081.

Westblade LF, Nussbaum AJ, McAdam AJ. Can You Speciate This for Me? A Micro-Comic Strip. J Clin Microbiol. 2019;57(7).

Kodiyanplakkal RP, Laplante JM, Westblade LF, Van Besien K, Salvatore M, St George K. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. Open Forum Infect Dis. 2019;6(12):ofz493.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(22):6839-6851.

Chidambaram S, Pannullo SC, Roytman M, Pisapia DJ, Liechty B, Magge RS, et al. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery. Neurosurg Focus. 2019;46(6):E10.

McIntire PJ, Snow JT, Elsoukkary SS, Soong L, Sweeney J, Robinson BD, et al. Digital image analysis supports a nuclear-to-cytoplasmic ratio cutoff value below 0.7 for positive for high-grade urothelial carcinoma and suspicious for high-grade urothelial carcinoma in urine cytology specimens. Cancer Cytopathol. 2019;127(2):120-124.

Droesch C, Magro C. A comedonal variant of chronic cutaneous lupus erythematosus: Case report and literature review. JAAD Case Rep. 2019;5(9):801-805.

Hamid AA, Gray KP, Shaw G, Macconaill LE, Evan C, Bernard B, et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019;76(1):89-97.

Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, et al. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(12):2047-2054.

Bartlett NL, Wilson WH, Jung S-, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.